Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
Samsung Electronics Sees Sustained AI-Driven Demand for Memory Chips Into Next Year 
Canadian Airlines Suspend Cuba Flights Amid Jet Fuel Shortage and U.S. Sanctions 
AST SpaceMobile Joins MSCI ACWI Index as Largest New Addition, Boosting Market Visibility 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
Treasury Wine Estates Shares Surge After U.S. Dispute Settlement and Earnings Upgrade 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
Salesforce Workforce Reduction Affects Fewer Than 1,000 Roles Amid Ongoing Restructuring 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
CARLSBAD, Calif., Feb. 21, 2018 -- GenMark Diagnostics, Inc. (NASDAQ:GNMK) today announced that the Company plans to participate in two upcoming investor conferences.
- March 1, 2018, GenMark’s management is scheduled to participate in the BTIG Snowbird Healthcare Conference in Snowbird, UT. Due to the format of this event, no webcast is available.
- March 14, 2018 at 10:00am ET, GenMark’s management is scheduled to present at the Cowen & Co. 38th Annual Health Care Conference in Boston, MA. Interested parties can access the live and archived webcast at www.genmarkdx.com, under the investor relations section.
ABOUT GENMARK DIAGNOSTICS
GenMark Diagnostics (NASDAQ:GNMK) is a leading provider of multiplex molecular diagnostic solutions designed to enhance patient care, improve key quality metrics, and reduce the total cost-of-care. Utilizing GenMark's proprietary eSensor® detection technology, GenMark's eSensor XT-8® and ePlex® systems are designed to support a broad range of molecular diagnostic tests with compact, easy-to-use workstations and self-contained, disposable test cartridges. GenMark’s ePlex: The True Sample-to-Answer Solution™ is designed to optimize laboratory efficiency and address a broad range of infectious disease testing needs, including respiratory, bloodstream, and gastrointestinal infections. For more information, visit www.genmarkdx.com.
Investor Relations Contact
Lynn Pieper Lewis or Leigh Salvo
(415) 937-5404
[email protected]
